Yáñez ÁI, Martínez SMF, Conde GCJ, García SAB, Sánchez AMÁ

Language: Spanish
References: 25
Page: 93-97
PDF size: 125.72 Kb.

ABSTRACT

Objective. To describe herpes simplex virus type 2 seroprevalence and seroincidence among persons living with HIV in the State of Morelos, Mexico.
Material and methods. HIV seropositive persons attended every six months to laboratory analyses for their follow up. Serum samples were analyzed to detect HSV-2 antibodies by ELISA methodology.
Results. The retrospective cohort began with 301 samples, HSV-2 seroprevalence was 48.5%, seroincidence was 38.5 new cases/100 person-years. Half of the persons HSV-2 seronegative at basal line were HSV-2 seropositive 21 months later.
Conclusions. High HIV/HSV-2 co-infection was detected; the co-infection could be the origin of quick AIDS progression and higher HIV transmission.

REFERENCES

1. Whitley RJ, Roizman B. “Herpes simplex virus infections”. Lancet 2001; 357: 1513-1518.

2. Gupta R, Warren T, Wald A. “Genital herpes”. Lancet 2007; 370: 2127-2137.

3. Wald A, Link K. “Risk of human immunodeficiency virus infection in herpes simplex virus type 2 seropositive persons: a meta-analysis”. J Infect Dis 2002; 185: 45-52.

4. Freeman EE, Weiss HA, Glynn JR, et al. “Herpes simplex virus 2 infection increases HIV acquisition in men and women: systematic review and meta-analysis of longitudinal studies”. AIDS 2006; 20: 73-83.

5. LeGoff J, Weiss HA, Gresenguet G, et al. “Cervicovaginal HIV-1 and herpes simplex virus type 2 shedding during genital ulcer disease episodes”. AIDS 2007; 21: 1569-1578.

6. Nagot N, Ouedraogo A, Konate I, et al. “Roles of clinical and subclinical reactivated herpes simplex virus type 2 infection and human immunodeficiency virus type 1 (HIV-1)-induced immunosuppression on genital and plasma HIV- Levels”. J Infect Dis 2008; 198: 241-249.

7. Schacker T, Zeh J, Hu HL, et al. “Changes in plasma human immunodeficiency virus type 1 RNA associated with herpes simplex virus reactivation and suppression”. J Infect Dis 2002; 1718-1725.

8. Celum CL, Robinson NJ, Cohen MS. “Potential effect of HIV type 1 antiretroviral and herpes simplex virus type 2 antiviral therapy on transmission and acquisition of HIV type 1 infection”. J Infect Dis 2005; 191 Suppl 1: S107-S114.

9. Hennessey KA, Giorgi JV, Kaplan AH, et al. “AIDS onset at high CD4+ cell levels is associated with high HIV load.” AIDS Res Hum Retroviruses 2000; 16: 103-107.

10. Schacker T, Zeh J, Hu HL, et al. “Frequency of symptomatic and asymptomatic herpes simplex virus type 2 reactivations among human immunodeficiency virusinfected men”. J Infect Dis 1998; 1616-162.

11. Eing BR, Lippelt L, Lorentzen EU, et al. “Evaluation of confirmatory strategies for detection of type-specific antibodies against herpes simplex virus type 2”. J Clin Micribiol 2002; 40: 407-413.

12. Abraham CD, Conde González CJ, Cruz Valdez A, et al. “Sexual and demohraphic risk factors for herpes simplex virus type 2 according to schooling level among Mexican youngs”. Sex Transm Dis 2003; 30: 549-555.

13. Sánchez Alemán MA, Conde González CJ, Gayet C, et al. “Sexual behavior and herpes simplex virus 2 infection in college students”. Arch Med Res 2005; 36: 574-580.

14. Gutiérrez JP, Bertozzi SM, Conde González CJ, et al. “Risk behaviors of 15-21 years olds in Mexico lead to a high prevalence of sexually transmitted infections: results of a survey in disadvantage urban areas”. BMC Public Helalth 2006; 6: 49.

15. Zamilpa Mejía LG, Uribe Salas F, Juárez Figueroa L, et al. “Prevalencia y factores asociados con sífilis y herpes genital en dos grupos de población femenina”. Salud Publica Mex 2003; 45 supl 5: s617-s623.

16. Conde González CJ, Lazcano Ponce E, Hernández Girón C, et al. “Seroprevalencia de la infección por el virus herpes simplex tipo 2 en tres grupos poblacionales de la ciudad de México”. Salud Publica Mex 2003; 45 supl 5: s608-s616.

17. Uribe Salas F, Hernández Avila M, Conde González CJ, et al. “Low prevalence of HIV and sexually transmitted disease among female commercial sex workers in Mexico City”. Am J Public Health 1997; 87: 1012-1015.

18. Uribe Salas F, Conde González CJ, Juarez Figueroa L, et al. “Socio-demographic characteristics and sex practices related with herpes simplex virus type 2 infection in Mexican and Central American fenale sex workers”. Epidemiol Infect 2003; 131: 859-865.

19. Uribe Salas F, Palma Coca O, Sánchez Alemán MA, et al. “Population-based prevalence of antibodies against herpes simplex virus type 2 and sociodemographic characteristics in Mexico”. Trans R Trop Med Hyg 2009; 103: 151-158.

20. Strick LB, Wald A, Celum C. “Management of Herpes Simplex Virus Type 2 infection in HIV Type 1-Infected Persons”. Clin Infect Dis 2006; 43: 347-356.

21. Centers for Disease Control and Prevention; Health Resources and Services Administration; National Institutes of Health; HIV Medicine Association of the Infectious Diseases Society of America, HIV Prevention in Clinical Care Working Group. “Recommendations for incorporating human immunodeficiency virus (HIV) prevention into the medical care of persons living with HIV”. Clin Infect Dis 2004; 38: 104-121.

22. Baeten JM, Strick LB, Lucchetti A, et al. “Herpes Simplex Virus (HSV)-Suppressive Therapy decreases plasma and genital HIV-1 levels in HSV-2/HSV-1 coinfected women: A randomized, placebo-controlled, cross-over trial”. J Infect Dis 2008; 198: 1804-1808.

23. Nagot N, Ouédraogo A, Foulongne V, et al. “Reduction of HIV-1 RNA levels with therapy to suppress herpes simplex virus”. N Eng J Med 2007; 356: 790-799.

24. Morin SF, Koester KA, Steward WT, et al. “Missed opportunities: Prevention with HIV-infected patients in clinical care settings”. J Acquir Immune Defic Syndr 2004; 36: 960-966.

25. Flaks RC, Burman WJ, Gourley PJ, et al. “HIV transmission risk behavior and its relation to antiretroviral treatment adherence”. Sexually Transmitted Diseases 2003; 30: 398-404.